Telapristone - Repros Therapeutics
Alternative Names: CBD4124; CDB-4124; Proellex; Proellex®-V; Progenta; Telapristone acetateLatest Information Update: 27 Feb 2023
At a glance
- Originator National Institute of Child Health and Human Development
- Developer Northwestern University Feinberg School of Medicine; Repros Therapeutics
- Class Antineoplastics; Antiprogestogens; Norpregnadienes; Small molecules
- Mechanism of Action Selective progesterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Uterine leiomyoma
- Suspended Anaemia; Endometriosis
Most Recent Events
- 14 Apr 2021 No development reported - Phase-II for Endometriosis in USA (PO) (NCT01728454)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in USA (Vaginal, Suppository)
- 17 Jul 2017 Repros Therapeutics completes a phase II trial in Endometriosis in USA and Argentina (NCT01728454)